Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge.

ABSTRACT:

Background

Ebola virus (EBOV), variant Makona, was the causative agent of the 2013-2016 West African epidemic responsible for almost 30,000 human infections and over 11,000 fatalities. During the epidemic, the development of several experimental vaccines was accelerated through human clinical trials. One of them, the vesicular stomatitis virus (VSV)-based vaccine VSV-EBOV, showed promising efficacy in a phase 3 clinical trial in Guinea and is currently used in the ongoing EBOV outbreak in the northeastern part of the Democratic Republic of the Congo (DRC). This vaccine expresses the EBOV-Kikwit glycoprotein from the 1995 outbreak as the immunogen.

Methods

Here we generated a VSV-based vaccine expressing the contemporary EBOV-Makona glycoprotein. We characterized the vaccine

SUBMITTER: Marzi A 

PROVIDER: S-EPMC6945200 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature